ReviewCureus2025
Histotripsy Compared With Microwave Ablation, Radiofrequency Ablation, and Stereotactic Body Radiotherapy for the Treatment of Liver Tumors.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer encompasses both primary and secondary malignancies, each carrying unique diagnostic and therapeutic challenges. The goals of conventional liver-directed treatments, including radiofrequency ablation, microwave ablation, and stereotactic body radiotherapy, are local tumor control and improved survival outcomes. However, these treatments are limited by the heat-sink effect, incomplete ablation around vascular structures, and risk of collateral tissue injury. These limitations have prompted the exploration of alternative, non-thermal, and minimally invasive options. Histotripsy is a novel ultrasound-based technique that uses focused mechanical cavitation, rather than heat, to fragment tumor tissue, while preserving surrounding bile ducts and blood vessels. Preclinical and early clinical data, including the THERESA and HOPE4LIVER trials, have demonstrated histotripsy's feasibility, safety, and precision, confirming its ability to generate sharply demarcated ablation zones with minimal complications. Without thermal injury, histotripsy offers a vessel-sparing, non-ionizing, and repeatable treatment alternative, especially for patients with lesions adjacent to critical structures or those not suitable for resection or heat-based ablation. This review summarizes current evidence, principles, and translational insights of histotripsy as a promising non-thermal ablative technology in the treatment of hepatic malignancies and highlights its potential role as a future standard in image-guided liver therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.